S
Supriya Lifescience
Leading developer of generic APIs and FDFs with global regulatory approvals and a diverse product portfolio
About Supriya Lifescience
Supriya Lifescience Limited, headquartered in Mumbai, India, is a public listed company specializing in the development and commercialization of generic Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). Established in 1987, the company operates in the pharmaceutical industry, serving a global clientele that includes healthcare providers and pharmaceutical companies. Supriya Lifescience's API facility in Lote, Maharashtra, has received multiple approvals from international regulatory bodies such as the USFDA, EDQM, EUGMP, and Health Canada, ensuring compliance with stringent quality standards.
The company's business model revolves around the production and sale of over 38 different APIs, which are used to treat various diseases and infections. These products are trusted by a loyal customer base worldwide. Revenue is generated through the sale of these APIs and FDFs to pharmaceutical companies and healthcare providers, who then use them in the production of medications.
Supriya Lifescience is committed to continuous improvement and innovation, as evidenced by its receipt of several national awards for excellence in R&D and entrepreneurship. The company's facility spans 47,000 square meters and includes dedicated areas for warehousing, quality assurance, quality control, research and development, production, and finished products. This infrastructure supports the company's mission to deliver high-quality pharmaceutical products while contributing to social upliftment and creating opportunities for a larger section of society.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPO✓Exit | Dec 2021 | $92M | — | Undisclosed | ↗ |
| LATE VC✓Equity / VC | Dec 2021 | $41M | $166M | Reliance General Insurance Company · BNP Paribas · Nippon India Mutual Fund · Saint Capital Fund | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later6 investors entered at this stage
Reliance General Insurance Company
BNP Paribas
Nippon India Mutual Fund- SFSaint Capital Fund
Societe Generale
Kuber India
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Supriya Lifescience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Supriya Lifescience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.